57 related articles for article (PubMed ID: 7710452)
21. Pharmacokinetics of natural human IFN-alpha in hemodialysis patients.
Gotoh A; Hara I; Fujisawa M; Okada H; Arakawa S; Kudo S; Obe T; Maruyama S; Sakai R; Kamidono S
J Interferon Cytokine Res; 1999 Oct; 19(10):1117-23. PubMed ID: 10547151
[TBL] [Abstract][Full Text] [Related]
22. Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
Sparano JA; Wadler S; Liebes L; Robert NJ; Schwartz EL; Dutcher JP
Cancer Res; 1993 Aug; 53(15):3509-12. PubMed ID: 8339255
[TBL] [Abstract][Full Text] [Related]
23. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of epirubicin in man. Non-influence of alpha interferon.
Eksborg S; Mattson K
Med Oncol Tumor Pharmacother; 1988; 5(2):131-3. PubMed ID: 3166083
[TBL] [Abstract][Full Text] [Related]
25. Effects of verapamil on the pharmacokinetics and metabolism of epirubicin.
Mross K; Hamm K; Hossfeld DK
Cancer Chemother Pharmacol; 1993; 31(5):369-75. PubMed ID: 8431970
[TBL] [Abstract][Full Text] [Related]
26. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic studies with 4'-epi-doxorubicin in nasopharyngeal carcinoma patients.
Hu OY; Chang SP; Jame JM; Chen KY
Cancer Chemother Pharmacol; 1989; 24(5):332-7. PubMed ID: 2758564
[TBL] [Abstract][Full Text] [Related]
29. Variability in the pharmacokinetics of epirubicin: a population analysis.
Wade JR; Kelman AW; Kerr DJ; Robert J; Whiting B
Cancer Chemother Pharmacol; 1992; 29(5):391-5. PubMed ID: 1551178
[TBL] [Abstract][Full Text] [Related]
30. Absorption of interferon alpha from patches in rats.
Ito Y; Tosh B; Togashi Y; Amagase K; Kishida T; Kishida T; Sugioka N; Shibata N; Takada K
J Drug Target; 2005 Jul; 13(6):383-90. PubMed ID: 16278158
[TBL] [Abstract][Full Text] [Related]
31. [Pharmacokinetics of epirubicin in cancer patients].
Ohno T; Shimoyama T; Kimura K; Yamada H
Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
[TBL] [Abstract][Full Text] [Related]
32. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
33. Effect of dosing schedule on pharmacokinetics of alpha interferon and anti-alpha interferon neutralizing antibody in mice.
Wang DS; Ohdo S; Koyanagi S; Takane H; Aramaki H; Yukawa E; Higuchi S
Antimicrob Agents Chemother; 2001 Jan; 45(1):176-80. PubMed ID: 11120962
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacokinetic aspects of the combination of interferon-alpha-2b and folic acid with fluorouracil].
Czejka MJ; Jäger W; Schüller J; Fogl U; Schernthaner G
Arzneimittelforschung; 1991 Aug; 41(8):860-3. PubMed ID: 1781811
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of doxorubicin and epirubicin in mice during chlorpromazine-induced hypothermia.
Lundgren-Eriksson L; Carlsson A; Eksborg S; Ryd W; Vesanen R; Hultborn R
Cancer Chemother Pharmacol; 1997; 40(5):419-24. PubMed ID: 9272119
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of 4' epi-adriamycin after morning and afternoon intravenous administration.
Eksborg S; Stendahl U; Antila K
Med Oncol Tumor Pharmacother; 1989; 6(3):195-7. PubMed ID: 2615523
[TBL] [Abstract][Full Text] [Related]
37. A pharmacokinetic model for alpha interferon administered subcutaneously.
Chatelut E; Rostaing L; Grégoire N; Payen JL; Pujol A; Izopet J; Houin G; Canal P
Br J Clin Pharmacol; 1999 Apr; 47(4):365-71. PubMed ID: 10233199
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
Scheithauer W; Schenk T; Czejka M
Br J Cancer; 1993 Jul; 68(1):8-9. PubMed ID: 8318424
[TBL] [Abstract][Full Text] [Related]
39. Percutaneous absorption of interferon-alpha by self-dissolving micropiles.
Ito Y; Saeki A; Shiroyama K; Sugioka N; Takada K
J Drug Target; 2008 Apr; 16(3):243-9. PubMed ID: 18365886
[TBL] [Abstract][Full Text] [Related]
40. Lean body mass, body surface area and epirubicin kinetics.
Cosolo WC; Morgan DJ; Seeman E; Zimet AS; McKendrick JJ; Zalcberg JR
Anticancer Drugs; 1994 Jun; 5(3):293-7. PubMed ID: 7919453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
